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PathogenesisAlopecia areata (AA) is a non-scarring inﬂammatory hair loss disease with a complex autoimmune
etiopathogenesis that is poorly understood. In order to investigate the pathogenesis of AA at the molecular
level, we examined the gene expression proﬁles in skin samples from lesional (n=10) and non-lesional sites
(n=10) of AA patients using Affymetrix Hu95A-v2 arrays. 363 genes were found to be differentially
expressed in AA skin compared to non-lesional skin; 97 were up-regulated and 266 were down-regulated.
Functional classiﬁcation of the differentially expressed genes (DEGs) provides evidence for T-cell mediated
immune response (CCL5, CXCL10, CD27, ICAM2, ICAM3, IL7R, and CX3CL1), and a possible humoral
mechanism (IGHG3, IGHM, and CXCR5) in AA. We also ﬁnd modulation in gene expression favoring cellular
proliferation arrest at various levels (FGF5, FGF18, EREG, and FOXC2) with apoptotic dysregulation (LCK,
TNF, TRAF2, and SFN) and decreased expression of hair follicle structural proteins. Further analysis of
patients with AAT (b1 year duration, n=4) and AAP (N1 year duration, n=6) of disease revealed 262 DEGs
distinctly separating the 2 groups, indicating the existence of gene proﬁles unique to the initial and later
stages of disease.sical Sciences Building, East
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Alopecia areata (AA), a non-scarring inﬂammatory hair loss
disease, is a complex disease determined by multiple genetic loci. It
involves immune dysregulation leading to hair loss with an estimated
lifetime incidence rate of 1.7% in the general population [1]. AA
presents most frequently as patchy hair loss on the scalp (and
sometimes other hair-bearing areas) that is either transient (AAT) or
persistent (AAP), but may progress into total scalp hair loss, alopecia
totalis (AT), or even complete body hair loss, alopecia universalis
(AU).
While the exact etiopathogenesis of AA remains unclear, there is
considerable evidence suggesting autoimmune [2], genetic [3], and
environmental factors in disease pathology. Various signaling mole-
cules mediate the transition through phases of the hair cycle involving
anagen (growth), catagen (regression), telogen (rest) and exogen
(shedding). The complex interplay between these factors may also
account for the extensive clinical heterogeneity seen in the disorder.
Evidence for a genetic basis in the pathogenesis of AA is derived from
the increased frequency of family history (reported by 20 to 42 % of
patients) [4], a 55% concordance rate among monozygotic twins, and
increased associations of speciﬁc HLA alleles, including HLA-DR4, DR5(DR11), and DQ3 in AA and HLA-DR5 (DR11) and DQ7 in long-
standing AT/AU [3]. Within the context of genetic predisposition, the
onset of AA may be triggered by several possible mechanisms
including environmental factors [including a viral etiology] [5,6] and
psychological stress [7,8]. Suggestion for autoimmune disease
mechanisms stems from a peribulbar and intrafollicular mononuclear
cell inﬁltrate (consisting of primarily CD4+ and CD8+ cells as well as
macrophages and Langerhans cells) which is closely associated with
dystrophic anagen stage hair follicles [9,10], and the increased
incidence of other autoimmune diseases (including thyroid disorders,
pernicious anemia and vitiligo) observed in probands as well as
unaffected relatives [4,11].
Despite strong evidence supporting a genetic basis for AA,
including a recent genomewide scan linkage analysis [12], there are
no conﬁrmed genetic susceptibility genes or markers of disease
induction and progression. The extent and mechanisms of genetic
contribution to the etiopathogenesis of AA remain elusive [3]. We
have examined gene expression directly in the skin tissues of patients
with AA to search for molecular links within the cascade of genetic
elements and immunologic interactions that coordinate the initiation
and progression of the disease process. We report patterns of gene
expression in 10 alopecia patients using oligonucleotide microarrays
that distinguish AA affected vs. unaffected skin and identify distinct
signatures of gene expression that further differentiate early vs. later
stages of disease. Examination of speciﬁc sequences within these
signatures provides evidence for immune activation, cell cycle
disruption, and apoptosis-related mechanisms of disease.
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Differential gene expression in AA lesional skin
A total of 20 human skin biopsies, lesional (n=10) and non-
lesional (n=10) skin from patchy alopecia areata patients, were used
for gene expression analysis (Table 1). After normalization per gene
per chip (see Materials and methods), statistical comparison of
lesional alopecia skin and non-lesional control skin returned 363
sequences differentially expressed between the 2 groups at Pb0.05.
We include all DEGs with a statistically signiﬁcant differential fold
change in our analysis since even minimal differences in gene
expression may be biologically signiﬁcant [13]. 97 DEGs were up-
regulated in the lesional samples (fold changes ranging from +1.1 to
+3.0) and 266 genes were down-regulated (fold changes ranging
from −1.1 to −6.7) (Supplemental Table 1). Gene KRT81 (keratin
81), located on the chromosome 12, showed the greatest fold change
with a down-regulation of 6.7-fold in AA skin. Several other acidic and
basic hair keratins were also found to be signiﬁcantly down-regulated
(KRT14, KRT31, KRT32, KRT33A, KRT33B, KRT34, KRT35, KRT4, KRT83,
KRT85, KRT86, and KRTAP26-1). The DEGs with the greatest up-
regulated fold change in AA skin were ADAM3A (Adam metallopepti-
dase domain 3a, +3.0 fold) and KLRD1 (Killer cell lectin-like receptor
subfamily D member 1, +2.8 fold).
To conﬁrm the direction of the change in gene expression observed
by themicroarray analysis, the fold changes for 4 genes –KRT81, KRT86,
HSPA2 and DTD (SLC26A2) – between paired lesional and non-lesional
samples determined by microarray data and real-time RT-PCR were
compared (Supplemental Fig. 1). We included both up- and down-
regulated, as well as minimally and highly differentially expressed
sequences (as determined by microarray) for analysis (KRT81: −11
fold, KRT86: −4.9 fold, HSPA2: −1.6 fold and DTD: +2.0 fold). The
relative fold changes for these 4 genes obtained by real-time PCR for the
skin samples analyzed correspondedwellwith fold changes determined
by microarray analysis. Correlation coefﬁcient (r2) observed between
the 2 methods was 0.9455 for gene KRT81, 0.9899 for gene KRT86,
0.7681 for gene HSPA2 and 0.6471 for DTD (SLC26A2), thus validating
our gene chip data.AA lesional skin signature reveals differential expression of genes
involved in immunity, cell cycle, apoptosis, and structural hair follicle
genes
To evaluate the alterations in gene expression that differentiate
lesional vs. non-lesional AA skin, we annotated the 363 DEGs into
known functional categories and performed pathway analyses gener-Table 1
Subjects participating in this study. Median age=38 years; median duration of
disease=3 years; early stage (b1 year duration)=4 subjects, late stage (N1 year
duration)=7 subjects; Caucasians=6 subjects, African Americans=1 subject, His-
panic=4 subjects. All patients were off therapy for more than 4 weeks and none had
documented therapy at the site of biopsy. Patient AA3006, however, was noted to have
completed a course of intralesional steroid at the site of biopsy 4 weeks prior to skin
sampling.
Patient Age (yr) Sex Ethnicity Type
AA1008 38 M Caucasian AAT
AA3001 37 F Hispanic AAT
AA3007 39 F Hispanic AAT
AA3008 38 F Hispanic AAT
AA1005 35 F African-American AAP
AA1006 42 F Caucasian AAP
AA1007 38 F Caucasian AAP
AA3006 39 F Hispanic AAP
AA1009 56 M Caucasian AAP
AA1010 28 F Caucasian AAPated by the DAVID database and PubMed literature searches (Fig. 1). 62
differentially modulated genes were found to be involved in immune
and inﬂammatory response. Among themwe found evidence for active
T-cell immunity at the site of pathology. For instance, genes CD27,
ICAM2 (CD102), and ICAM3 (CD50) are reported to be essential for
dendritic cell–T-cell adherence and T-cell activation [14]. The up-
regulation of LCK and fractalkine (CX3CL1) suggest an IFN-γ-mediated
Th1 type of response,while the up-regulation of IRF7 and ISG15 suggest
a role for IFN-alpha in lesional AA skin tissue. ISG15 is one of the earliest
and most predominant proteins to be induced in mammals following
IFN-alpha/beta stimulation [15], while IRF7 is essential for the
transcriptional activation of IFN-alpha genes [16]. Up-regulation of
CD4 antigen (an accessory protein for MHC class-II antigen/T-cell
receptor interaction) [17] and down-regulation of MRC2 (a mannose
receptor on macrophages involved in endocytic protein clearance) [18]
suggest an enhanced antigen presentation activity in the lesional AA.
Along with these indications of an enhanced T-cell response, we
also observe an up-regulation of CXCR5 (CD185), a cytokine receptor
that is essential in B-cell migration and localization. IGHG3 (immu-
noglobulin heavy constant-γ-3/G3m marker; +2.7 fold) and IGHM
(immunoglobulin heavy locus; +1.7 fold) were also up-regulated in
AA skin compared to normal controls, suggesting active immuno-
globulin production in lesional AA skin.
Another 27 differentially regulated genes participate in cell cycle
processes, including 7 genes involved in mitosis at various points and
6 involved in DNA repair and replication. Among the genes involved in
mitotic processes are FGF5, FGF18, cyclin M2, CDC27, SPC25, EREG,
and PPP2R1B. Positive signals for cell division like PPP2R1B, CDC27,
FGF5, FGF18, and cyclin M2 are down-regulated in AA skin. Six DEGs
participating in DNA repair and replicative processes were down-
regulated, including RAD51L3, RPA3, SFN (stratiﬁn), DNA2, and
TERF2. TERF2 is known to protect against end-to-end fusion of
chromosomes and plays a role in successful progression through the
cell division cycle. Overall, these observations suggest inhibition of
cellular proliferation in AA affected skin.
Genes encoding heat shock and related proteins (HSPA2 and
HSPA5) were found to be down-regulated in AA, as well as the stress-
related gene MT4 (metallothionein 4), which may regulate zinc
metabolism during differentiation of stratiﬁed epithelia [19]. Genes
participating as signals in hair follicle morphogenesis and cycling,
FGF5, FZD1, and BMP2, were down-regulated in AA lesional skin
[20,21]. The reduced expression of these genes suggests arrested
follicular development and cycles. Seventeen down-regulated DEGs
code for structural and cytoskeletal proteins, including several acidic
and basic hair keratins and tubulins. We additionally report 24 DEGs
as miscellaneous since the exact functions of these genes are not
identiﬁed yet. Finally, it should be noted that the functional
annotations reported overlap for several genes. For instance, the
gene EREG (epiregulin) is involved in immune system mechanisms,
although the primary functions include stimulating localized cell
proliferation and/or angiogenesis.
As discussed above, a previous report identiﬁed several mouse and
human genes through microarray which may be relevant to disease
pathogenesis [22]. In comparing our list of DEGs with the previous
study, we found 11 overlapping DEGs with corresponding dysregula-
tion in diseased skin compared to normal skin. These genes include six
down-regulated hair keratin genes and up-regulation of immune
system-related genes (LCK and ISG15).
Overall, functional classiﬁcation DEGs suggest active immune
mechanisms of disease; there is evidence for active antigen
presentation, T-cell (Th1) mediated immunity, and humoral activity.
Further, we report disruption of cell cycle pathways within lesional
skin, with inhibition of cellular proliferation and up-regulation of
apoptosis. Finally, there is evidence for an arrest of hair follicle cycling
and regeneration with the resultant down-regulation of hair-related
keratins. Fig. 2 provides a visual representation of the sequence of
Fig. 1. Differential expression of genes reveals ontologies and pathways active in lesional skin. 363 genes were found to be differentially expressed in AA lesional skin as compared to
non-lesional skin with a P-valueb0.05, followed by functional annotation by DAVID. Bars indicate fold change levels along the x-axis.
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may contribute to hair loss.
Comparison of transient vs. persistent AA lesional skin reveals
differential expression of epidermal differentiation, cell proliferation,
and apoptosis
To better understand mechanisms related to disease progression,
we next analyzed gene expression differences between alopeciaareata, patchy transient (b1 year; AAT) (n=4) and alopecia areata,
patchy persistent (N1 year; AAP) (n=6). To explore the similarities
and differences in global gene expression patterns among the samples
without a priori knowledge of sample identity, we employed an
unsupervised hierarchical clustering method using the 98 probe sets
with the highest variation across samples (Fig. 3). This unbiased
approach was able to differentiate transient (AAT) vs. persistent
(AAP) lesional skin, indicating that gene expression analysis may be
able to classify samples by disease evolution.
Fig. 2. Possible pathogenetic events supported by microarray data. Immune dysregulation underlying arrested follicular development, ultimately leading to loss of hair keratins and
clinical hair loss. Genes up-regulated in AA are shown in red and those down-regulated are shown in blue.
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of 262 genes at Pb0.05 depending on duration of disease; 129
sequences were up-regulated in AAT and 133 were up-regulated in
AAP samples (Supplemental Table 2). GJB3 (connexin 31) had the
highest fold change in AAT (+11.8); it is expressed in the stratum
granulosum of the epidermis with a suggested role in late keratino-
cyte differentiation [23]. On the other hand, CD72 antigen (Lyb-2) had
the highest fold change in AAP (+8.3); it plays a key role in B-cell
proliferation and differentiation by associating with CD5 [24]. LOR
(loricrin), FLG (ﬁlaggrin), KLK7 (kallikrein 7), and KLK13 (kallikrein
13) are all down-regulated in AAP, perhaps representing markers of
disease progression from early to later stages. Finally, several
ﬁbroblast growth factors (FGF6, FGF9, FGF13 and FGF18) were up-
regulated in AAP. While the role of FGFs on hair follicles are poorly
understood, studies have shown a suppression in follicle initiation and
development causing delayed hair cycling, as well as a decreased
anagen:telogen ratio [25].
Discussion
In this study we examined gene expression proﬁles in alopecia
areata to deﬁne disease-speciﬁc signatures that may advance our
understanding of the pathogenesis and progression of disease. This
study provides a foundation for unraveling the, so far, poorly deﬁned
pathogenetic mechanisms operative in AA.
A previous study [22] reported gene expression patterns in a total
of 4 patients [2 AT, an AU, and an androgenetic alopecia patient], along
with an analysis of induced alopecia areata in the C3H/HeJ murine
model using Affymetrix mouse 11K and HuFL gene chips (6800
genes). Our investigation using Affymetrix Hu95A chip (12,627
genes) focused on patients with conﬁrmed AA and was performed
on a larger sample size (n=20). In comparing gene lists, only 11 DEGs
were found to be common between the studies. These 11 overlaps
reveal an analogous up-regulation of immune system-related genes
and down-regulation of hair keratin genes in both datasets that
supports an active immune process and loss of structural proteins
essential to hair follicles in AA. The overall paucity of matching genes
between the studies may be a function of the smaller sample size and
gene chip in the previous study, and/or patient heterogeneity.
The suggestion that AA is an autoimmune disease is derived from
several sources of evidence [2], including the intrafollicular inﬁltra-
tion of anagen follicles by activated T cells, macrophages, and
Langerhans cells, as well as the efﬁcacy of immunomodulators ondisease [26]. Our microarray data support the concept of immune
dysregulation in AA. Nearly 22% of the DEGs encode immune
regulators and pro-inﬂammatory proteins, providing evidence for
both cellular and humoral immunity involvement in AA.
Perivascular, peribulbar, and intrabulbar inﬂammatory inﬁltrates
in areas of hair loss are comprised of T cells (CD4NCD8), macrophages,
B cells, and NK cells, with increased inﬁltration in the early,
progressive phase of disease as compared to the later, stabilized
phase. Thus, it is likely that inﬁltrating lymphocytes contribute to the
differential gene expression differences found between lesional and
non-lesional skin. Accordingly, we do ﬁnd up-regulation of genes such
as LCK, a lymphocyte-speciﬁc tyrosine kinase, and CD4 surface antigen
in lesional that demonstrate active T-cell speciﬁc gene expression.
Cytokines (CX3CL1, CXCL1, CCL5, and CXCL10) involved in cellular
immunity were overexpressed in AA skin. CX3CL1 is not only induced
by IFN-γ, but also acts as an ampliﬁcation circuit of polarized Th1
responses [27], indicating a Th1 type of response in AA skin. Increased
expression of CCL5 (RANTES), an IL-1 beta and TNF-alpha inducible
gene, also suggests Th1 pathway activity [28]. Up-regulation of ICAM2
and ICAM3 in AA skin supports a mechanism allowing enhanced
antigen-speciﬁc immune responses through increased dendritic cell
(DC) migration and DC–T-cell interaction [29] in lesional skin. Our
observation in human AA skin tissue is consistent with the
observation of a Th1 response in the C3H/HeJ murine AA model [22].
Due to the absence of MHC class I (MHC I) expression in the distal
hair follicle epithelium, it has been suggested that the human anagen
hair bulb is a site of immune privilege [30]. Our data reveals decreased
expression of TGFB1 (transforming growth factor, beta 1), a potent
suppressor of MHC I expression, in lesional skin of AA patients. Our
data also support a possible role for IFN-α in AA, evidenced by the up-
regulation IFN-α related genes (ISG15 and IRF7) in AA lesional tissue
[31]. Furthermore, lesional AA skin showed increased expression of
TLR3, which, in conjunction with IFN-α, triggers MHC I up-regulation
and subsequent T-cell autoreactivity [32]. IFN-α inducible pathways
have been recently documented in lupus erythematosus and have
been postulated to play a role in breaching immune tolerance that
may be related to the regulation of dendritic cell maturation [33].
Thus, impaired immunosuppression and enhanced expression of
MHCI in lesional skin likely contributes to the collapse of immune
privilege at the hair follicle, and thus, recognition of self-antigens
leading to overt autoimmune disease.
Although our data clearly support a cellular immune response,
there has also been data to indicate that humoral mechanisms may
150 R.D. Subramanya et al. / Genomics 96 (2010) 146–153contribute to AA. We found that CD27 is up-regulated in lesional skin
suggesting active T-cell mediated B-cell activation and immunoglob-
ulin synthesis. The participation of humoral mechanisms is further
supported by the increased expression of IGHG3 (immunoglobulin
heavy constant-γ-3) and IGHM (immunoglobulin heavy constantmu)
in lesional AA skin compared to normal skin. Taken together, our data
supports the notion that humoral mechanisms may be at play
alongside cellular immunity. Nevertheless, whether antibody re-
sponse in AA is relevant in disease induction and/or progression or
simply represents an immunological epiphenomenon is at this point
unclear.
Despite the clear importance of lymphocyte activation in AA, the
identiﬁcation of autoantigen triggers of disease and/or targets of
autoimmune attack has remained elusive. Our data do, however,
provide direct evidence that an active antigen processing and
presentation is operational in AA lesional skin. MRC2 (also called
ENDO180), a marker of the mannose-receptor family shown to
facilitate phagocytosis, is suggested to play a role in tethering particles
and engaging a classical phagocytic receptor to drive phagocytic
machinery [34]. The down-regulation of MRC2 seen in AA perhaps
suggests decreased antigen clearance from the matrix of the skin,
which may promote autoimmune recognition and subsequent
activation. Alternatively, the overexpression of MRC2 in non-lesional
sites may imply a protective mechanism through enhanced antigen
clearance.
While immune attack is clearly evident, the ﬁnal effector mechan-
isms that result in target tissue damage in AA are not known. Our study
provides evidence for a global inhibition of cellular proliferation in
skin. There is down-regulation of genes involved in mitosis, including
EREG (epiregulin), FGF18 and PPP2R1B. Epiregulin stimulates kerati-
nocyte proliferation [35], while FGF18 and PPP2R1B (via down-
regulation of MAPK kinase pathway) are known to relay signals for
cellular proliferation [36]. Down-regulation of CDC27 suggests a block
in cell cycle progression through disruptions in mitotic spindle
formation and anaphase induction. We also found a potential
impairment of DNA repair based on down-regulation of TERF2
(telomeric repeat binding factor 2) and SFN (stratiﬁn). SFN acts at
the G2 check point, preventing mitotic death with its inactivation
inﬂuencing telomere behavior and ionizing radiation-induced chro-
mosomal instability [37]. Decreased expression of SFN implicates
increased DNA errors in daughter cells which can lead to “mitotic-
catastrophe” and apoptosis [38]. The PAK2 gene (p21 protein (Cdc42/
Rac)-activated kinase 2) was also down-regulated in lesional AA
samples. PAK2, expressed in response to stress stimulants, stimulates
cell survival by inhibiting phosphorylation and inhibition of pro-
apoptotic genes [39]. To add to this, the down-regulation of heat shock
proteins (HSPA2 and HSPA5) also suggests reduced inhibition of
apoptosis [40]. These ﬁndings parallel the systemic up-regulation of
apoptosis-related genes in AA patient blood [51]. Thus, we show
evidence for an overall inhibition of cellular proliferation and
execution of apoptosis in AA skin. Whether apoptosis in AA is
occurring in inﬁltrating immune cells or hair follicular cells is unclear.
The speciﬁc localization of apoptotic events and their role in disease
induction and/or target damage remains to be determined.
We also ﬁnd evidence for disruption of the follicular developmental
cycle and follicularmorphogenesis in AA skin. Actions of canonicalWNT
(Wingless-type MMTV) proteins in the skin are essential for generation
of the ﬁrst dermal message in hair follicle formation, even in postnatal
life [41,42]. FZD1 (frizzled homolog 1), up-regulated in AA lesional skin,
is a receptor for both canonical and non-canonical WNT signalingFig. 3. Unsupervised hierarchical clustering differentiates early vs. late AA skin.
Unsupervised hierarchical clustering of the 98 genes of highest variance across samples
from 10 AA lesional and non-lesional skin samples. Each row signiﬁes one of the 98
genes, while the columns represent samples in processed by a Euclidean distance
algorithm in dChip. Expression value intensities are illustrated by the color scale with a
range of −3 to 3 on a log2 scale.
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withhighest expression in cells of the developing outer root sheath [21].
While the exact role is uncertain, this expression may reﬂect poorly
coordinated hair follicle cycling, and thus, follicular arrest. FGF18, highly
expressed in hair follicles and capable of inducing anagen from telogen
stage hair follicles [43], is a direct target and known marker of the Wnt
signaling pathway that is down-regulated in AA lesional skin. Recent
work from our group in AA patient blood also showed down-regulation
of the Wnt/β-catenin signaling pathway through up-regulated Wnt
suppressors [51], suggesting that a systemic overexpression of Wnt/β-
catenin signaling inhibitors may predispose an individual to developing
AA. Finally, FGF5, important for determining the timing of active hair
growth (anagen) and transition into follicular regression (catagen) [44],
is down-regulated in AA lesional skin. Taken together, our data provide
solid support for dysfunctional coordination of follicular cycling and
development.
Genes related to cellular structure and encoding cytoskeleton
components form a substantial group of the DEGs observed in AA.
Decreased expression of hair structure-related genes is likely to
represent the ﬁnal marker of effective hair loss. Decreased expression
of KRT81 (basic hair keratin 1) and KRT86 (basic hair keratin 6) are
also seen inMonilethrix [45], where patients present with alopecia and
perifollicular hyperkeratosis (OMIM IDs: 602153 and 601928 respec-
tively). Among the other structural/cytoskeleton related sequences
that are down-regulated are several acidic and basic hair keratins and
alpha- and beta-tubulins. The CRIP2 gene (previously reported to be
one of the keratin associated proteins possibly involved in the human
trichothiodystrophy) [46] and another skin structure-related gene
KRT14 (whose mutation was noted in epidermolysis bullosa) were
also down-regulated in AA skin [47].
In addition to deﬁning a disease-associated signature, we
compared the AA affected samples that were obtained from subjects
within 1 year of AA onset (AAT) and those from more than 1 year
onset (AAP) in order to understand the kinetics of molecular events
that occur in the different stages of AA. Unsupervised hierarchical
clustering analysis of expression proﬁles between AAT and AAP
patients clearly distinguishes the samples for duration (AAT vs. AAP),
but also separates samples based on ethnicity. The effect of patient
variables, such as ethnicity, on gene expression in human skin is
poorly understood and likely to be subtle [48,49], thus not obscuring
the AA disease process from valid analysis. Ultimately, future studies
with larger cohorts will be required to validate the presence of distinct
gene expression proﬁles based on disease duration.
Evaluation of genes that are preferentially expressed in the initial
stages of the disease focuses examination on events related to disease
induction and early pathogenesis. Of speciﬁc interest are: FGFs 6, 9,
13, and 18, leukocyte membrane antigen (CD300A), and IFN-alpha 21,
which are up-regulated in AAP, and structure-related genes FLG,
CDSN, and LOR (encoding the structural proteins ﬁlaggrin, corneo-
desmosin, and loricrin, respectively), and KLK7 (kallikrein7) and
KLK13 (kallikrein13), which are down-regulated in AAP. However,
our current data is a cross-sectional representation of early vs. late
stage AA skin samples. Studies at sequential points in time, with skin
samples from the same subjects collected prospectively will be
needed to fully understand how the gene expression proﬁle changes
with clinical deterioration or improvement of AA.
In summary, our study of gene expression in AA was designed to
gain a better understanding of themolecular pathways involved in the
pathogenesis of AA through a non-reductionist approach. Our data
support the hypothesis that disease is initiated and perpetuated by
unknown autoantigens, perhaps localized within hair follicles,
presented to T cells via skin resident antigen presenting cells i.e. the
disease is antigen driven locally. A consequent Th1 type response is
activated with an unknown extent of involvement of humoral
immunity. The exact effector mechanisms by which T- and/or B-
lymphocytes result in hair loss remain unknown. However, our datasuggest that the self-directed immune response in AA leads to a block
in the progression of hair follicular cycle, perhaps related to increased
apoptosis in the follicular unit with a cessation of morphogenesis such
that the formation of new hair follicles is inhibited.
Materials and methods
Tissue procurement and handling
Subjects were identiﬁed to have AA based on established clinical
and histological criteria [50] at the Dermatology outpatient clinic of
New York Presbyterian Hospital – Cornell University. Informed
consent was obtained in each case (IRB# 0998-398) and two punch
biopsies of 6 mm each were performed on each of 10 patients under
local anesthesia (1% lidocaine with 1/100,000 epinephrine). The skin
tissues so procured corresponded to lesional alopecic skin to
represent the diseased sample and paired site-matched non-lesional
skin as a normal control sample from the same individual. Specimens
were snap-frozen in liquid nitrogen immediately after biopsy. Ten
patients had alopecia areata (AA) and one had alopecia universalis
(AU) (Table 1). Thus, a total of 20 biopsies (10 lesional and 10 non-
lesional) were used for gene expression analysis (Table 1). We further
classiﬁed the 10 AA patients to be AAT (n=4) (within 1 year of the
onset of ﬁrst patch), and AAP (n=6) (greater than 1 year after disease
onset) based on published investigational assessment guidelines [50].
All patients were off therapy for at least 4 weeks and none had
documented therapy at the site of biopsy (subject AA3006 completed
a course of intralesional steroid therapy at the site of biopsy 4 weeks
prior to skin sampling).
Target preparation
Total RNA was prepared from each sample using TRIzol reagent as
recommended by the manufacturer (GIBCO, Carlsbad, CA) and
subsequently puriﬁed using the RNeasy Mini kit (Qiagen, Chatsworth,
CA). Quantity and quality of total RNA were assessed by spectropho-
tometry. 16 µg total RNA per sample was used to synthesize cDNA
serving as a template for generation of biotinylated cRNA. Fragmented
cRNA was hybridized to Human Genome U95A arrays (Affymetrix,
Santa Clara, CA) for 16 h at 45 °C. Chips were then washed, stained
and scanned as per GeneChip Expression Analysis Manual protocol
(Affymetrix).
Analysis
Affymetrix Human Genome U95A microarrays were used for
hybridization and screening of 12,627 genes. Data obtained (by
scanning) were ﬁrst analyzed using Affymetrix's MicroArray Suite v5
(MAS5). Metrics ﬁles were then loaded into dChip for further analysis.
Quality control and per chip-per gene normalization
Before data normalization, consistency in quality of all 20 (10
lesional and 10 non-lesional) was checked using scatter plots,
correlation tests, and sample trees in order to eliminate any outlier
sample. There was a strong correlation in global gene expression
among all subjects analyzed (r2N0.79). Median polishing method was
applied to normalize raw gene expression values. First, all of the
measurements on each chip were divided by the 50th percentile
value. The bottom 10th percentile was used as a test for correct
background subtraction. Second, each gene was normalized to its
median. Further, consistency in the quality of samples was analyzed
using scatter plots and correlation tests.
Statistical comparison
Genes that were not expressed in any of the 20 samples were then
ﬁltered out and a list of genes in which each gene was present in at
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between the lesional and non-lesional samples was performed using
the Benjamini–Hochberg equation (false discovery rate of 5%) with a
P-value cut-off set to 0.05 which returned differentially expressed
genes (DEGs) between the 2 groups. Relative fold change in
expression of each of the DEGs was obtained by the ratio of median
normalized signal in the AA lesional skin to the median normalized
signal in non-lesional skin samples. A second analysis using only the
10 AA lesional samples to obtain the expression proﬁle between AAT
(n=4) and AAP (n=6) stages was performed using Benjamini–
Hochberg equation and P-value cut-off to 0.05.
Real-time RT-PCR
Total RNA from matched pairs of skin samples, where sufﬁcient
amounts of total RNA were available after microarray analysis, was
used as a template for real-time quantitative RT-PCR to conﬁrm the
validity of microarray in 4 randomly selected genes: KRT81, KRT86,
HSPA2 and DTD (SLC26A2). Twenty samples were used for genes
KRT81 and HSPA2, and 18 samples for genes KRT86 and DTD
(SLC26A2). The resulting fold changes between lesional and non-
lesional skin specimens from 10 AA patients were compared with
those calculated by microarray analysis.
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